Method of complex therapy of chronic cystitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To assess the effectiveness of hydroxyethyldimethyldihydropyr imidine (trade name Xymedone) in the treatment of chronic recurrent cystitis in women. Materials and methods. The study included 30 patients (the main group) with a confirmed diagnosis of chronic cystitis (HC) with a recurrence rate of at least 3 times a year, the average age of the patients was 46.0+2.7 years. The control group consisted of 30 age-comparable patients with a similar diagnosis, who underwent standard treatment for this disease. The article presents the results on the effectiveness of the use of hydro xyethyldimethyldihydropyrimidine (Xymedone) in the treatment of HC after anti-inflammatory and local treatment with collargol instillations, and the terms for the regeneration of the bladder mucosa are determined. To patients of the main group Xymedone was prescribed in a dose of 500 mg 3 times a day for 30 days after the completion of local treatment. Control cystoscopy was performed 15 and 30 days after the start of the drug, 3 days after its withdrawal. Results. The planned treatment was completed by all 30 patients of the main group. After 15 days from the date of administration of Xymedone most of patients had no low urinary tract symptoms (LUTS), in comparison with the control group. Cystoscopy performed at this time allowed to establish a positive trend while taking Xymedone in the process of restoring the bladder mucosa after influence of collargol. Hyperemia in the neck and triangle area persisted in most patients, and only in 8 (26.6%) it decreased. Treatment with Xymedone was continued. After 30 days of drug intake laboratory parameters were according to normal values, a significant increase in functional capacity of the bladder (189,5+19,8 ml) and volume of urination (147,9+26,7 ml.) was detected, the thickness of the bladder wall in a state of filling in the averages was 3.5+ 0.3 mm, which corresponded to the norm. Cystoscopy, performed 3 days after canceling of the drug, showed a slight hyperemia in the bladder neck area only in one patient. Recurrence of HC in the control group occurred within 6 months after completion of treatment in 15 (51%) women. In the main group there were no relapses during two years of dynamic follow-up. Conclusions. Hydroxyethyldimethyldihydropyrimidine, included in the therapy of HC, accelerates the regeneration of the bladder mucosa after local treatment of recurrent cystitis and shortens the period of its recovery, significantly lengthens the period of persistent remission.

Full Text

Restricted Access

About the authors

M. E. Sitdykova

Kazan State Medical University of the Ministry of Health of Russia

Email: marina-sitdykova@mail.ru
MD, Professor, Head of the Department of urology named after academician E.N. Sitdykov of the Kazan State Medical University of Ministry of Health of Russia, Honored doctor of the Republic of Tatarstan, Honored doctor of the Russian Federation Kazan, Russia

E. E Nikolsky

Kazan State Medical University of the Ministry of Health of Russia

Academician of the Russian Academy of Sciences, MD, Professor, Department of medical and biological physics of the Kazan State Medical University of Ministry of Health Russia, Honored worker of science of the Russian Federation Kazan, Russia

O. A Birchuk

Kazan State Medical University of the Ministry of Health of Russia

urologist of the urological Department of the «Medical University clinic» Kazan, Russia

D. R Sayapova

Kazan State Medical University of the Ministry of Health of Russia

Ph.D., assistant of the Department of urology named after academician E. N. Sitdykov Kazan, Russia

References

  1. Перепанова Т.С., Волкова Е.М. К вопросу патогенеза рецидивирующей инфекции нижних мочевыводящих путей. Экспериментальная и клиническая урология. 2015;(3):100-105
  2. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. М.: ГЭОТАР-Медиа, 2018
  3. Клинические рекомендации по инфекциям в урологии. Европейская ассоциация урологов, 2019
  4. Неймарк А.И., Неймарк Б.А., Сопотов А.В. Коррекция нарушений микроциркуляции у больных хроническим циститом с использованием пелоидотерапии. Современные проблемы науки и образования. 2015;(5):139
  5. Слесаревская М.Н., Кузьмин И.В., Жарких А.В., Шабудина Н.О. Оценка состояния микроциркуляции в стенке мочевого пузыря у женщин с хроническим рецидивирующим циститом. Урологические ведомости 2012; 2(2);26-31
  6. Переверзев А.С., Коган М.И. Инфекции и воспаление в урологии. М.: АБВ-пресс, 2007:224
  7. Измайлов С.Г., Измайлов Г.А., Аверьянов М.Ю., Резник В.С. Ксимедон в клинической практике. Нижний Новгород, 2001:188
  8. Перепанова Т.С., Козлов Р.С., Руднов В.А., Синякова Л.А. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М., 2015:72
  9. Капустин С.В., Оуен Р., Пиманов С.И. Ультразвуковое исследование в урологии и нефрологии. Минск: Вараксин, 2007:176
  10. Фазылов В.Х. Применение Ксимедона в клинической практике. Методические рекомендации для врачей. Казань, 2010:36
  11. Патент на изобретение «Лекарственное средство в комплексной терапии хронического цистита и способ комплексной терапии хронического цистита» № 2659199 от 28.06.2018, авторы Ситдыкова М.Э., Никольский Е.Е

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies